124 related articles for article (PubMed ID: 38589367)
1. Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1-mutant myelodysplastic syndromes.
Dolatshad H; Pellagatti A; Liberante FG; Llorian M; Repapi E; Steeples V; Roy S; Scifo L; Armstrong RN; Shaw J; Yip BH; Killick S; Kušec R; Taylor S; Mills KI; Savage KI; Smith CW; Boultwood J
Leukemia; 2016 Dec; 30(12):2322-2331. PubMed ID: 27211273
[TBL] [Abstract][Full Text] [Related]
2. Predicting survival in patients with myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis.
Li F; Qin T; Li B; Qu S; Pan L; Zhang P; Sun Q; Cai W; Gao Q; Jiao M; Li J; Ai X; Ma J; Gale RP; Xu Z; Xiao Z
Leukemia; 2024 Jun; 38(6):1334-1341. PubMed ID: 38714876
[TBL] [Abstract][Full Text] [Related]
3. Vitamin B5 and succinyl-CoA improve ineffective erythropoiesis in
Mian SA; Philippe C; Maniati E; Protopapa P; Bergot T; Piganeau M; Nemkov T; Di Bella D; Morales V; Finch AJ; D'Alessandro A; Bianchi K; Wang J; Gallipoli P; Kordasti S; Kubasch AS; Cross M; Platzbecker U; Wiseman DH; Bonnet D; Bernard DG; Gribben JG; Rouault-Pierre K
Sci Transl Med; 2023 Mar; 15(685):eabn5135. PubMed ID: 36857430
[TBL] [Abstract][Full Text] [Related]
4. Targeting the EIF2AK1 Signaling Pathway Rescues Red Blood Cell Production in SF3B1-Mutant Myelodysplastic Syndromes With Ringed Sideroblasts.
Adema V; Ma F; Kanagal-Shamanna R; Thongon N; Montalban-Bravo G; Yang H; Peslak SA; Wang F; Acha P; Sole F; Lockyer P; Cassari M; Maciejewski JP; Visconte V; Gañán-Gómez I; Song Y; Bueso-Ramos C; Pellegrini M; Tan TM; Bejar R; Carew JS; Halene S; Santini V; Al-Atrash G; Clise-Dwyer K; Garcia-Manero G; Blobel GA; Colla S
Blood Cancer Discov; 2022 Nov; 3(6):554-567. PubMed ID: 35926182
[TBL] [Abstract][Full Text] [Related]
5. Mutations in the splicing factor SF3B1 are linked to frequent emergence of HLA-DR
Winter S; Schneider M; Oelschlaegel U; Maggioni G; Riva E; Raddi MG; Bencini S; Peruzzi B; Choy D; Antunes Dos Reis R; Güse E; Lischer C; Vera J; Timms JA; Sompairac N; Sockel K; Poloni A; Tunger A; Della Porta MG; Santini V; Schmitz M; Platzbecker U; Kordasti S
Leukemia; 2024 Jun; 38(6):1427-1431. PubMed ID: 38632316
[No Abstract] [Full Text] [Related]
6. Impaired binding affinity of YTHDC1 with METTL3/METTL14 results in R-loop accumulation in myelodysplastic neoplasms with DDX41 mutation.
Hwang WC; Park K; Park S; Cheon NY; Lee JY; Hwang T; Lee S; Lee JM; Ju MK; Lee JR; Kwon YR; Jo WL; Kim M; Kim YJ; Kim H
Leukemia; 2024 Jun; 38(6):1353-1364. PubMed ID: 38514771
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Analyses of the Effects of the Small-Molecule Inhibitor of the UHM Domain in the Splicing Factor
Yuan X; Sabzvar MK; Patil AD; Chinnaswamy K; Howie KL; Andhavaram R; Wang B; Siegler MA; Dumaz A; Stuckey JA; Corey SJ; Maciejewski JP; Visconte V; Yang CY
Res Sq; 2024 Jun; ():. PubMed ID: 38883705
[TBL] [Abstract][Full Text] [Related]
8. Mis-splicing of mitotic regulators sensitizes SF3B1-mutated human HSCs to CHK1 inhibition.
Sarchi M; Clough CA; Crosse EI; Kim J; Baquero Galvis LD; Aydinyan N; Wellington R; Yang F; Galli A; Creamer JP; Stewart S; Bradley RK; Malcovati L; Doulatov S
Blood Cancer Discov; 2024 Jun; ():. PubMed ID: 38856693
[TBL] [Abstract][Full Text] [Related]
9. PARP inhibition leads to synthetic lethality with key splicing-factor mutations in myelodysplastic syndromes.
Zhang F; Sun J; Zhang L; Li R; Wang Y; Geng H; Shen C; Li L; Chen L
Br J Cancer; 2024 May; ():. PubMed ID: 38806724
[TBL] [Abstract][Full Text] [Related]
10. Mutational analysis of splicing machinery genes SF3B1, U2AF1 and SRSF2 in myelodysplasia and other common tumors.
Je EM; Yoo NJ; Kim YJ; Kim MS; Lee SH
Int J Cancer; 2013 Jul; 133(1):260-5. PubMed ID: 23280334
[TBL] [Abstract][Full Text] [Related]
11. Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications.
Pellagatti A; Boultwood J
Adv Biol Regul; 2017 Jan; 63():59-70. PubMed ID: 27639445
[TBL] [Abstract][Full Text] [Related]
12. Splicing Factor Mutations in Myelodysplasias: Insights from Spliceosome Structures.
Jenkins JL; Kielkopf CL
Trends Genet; 2017 May; 33(5):336-348. PubMed ID: 28372848
[TBL] [Abstract][Full Text] [Related]
13. Accelerated DNA replication fork speed due to loss of R-loops in myelodysplastic syndromes with SF3B1 mutation.
Rombaut D; Lefèvre C; Rached T; Bondu S; Letessier A; Mangione RM; Farhat B; Lesieur-Pasquier A; Castillo-Guzman D; Boussaid I; Friedrich C; Tourville A; De Carvalho M; Levavasseur F; Leduc M; Le Gall M; Battault S; Temple M; Houy A; Bouscary D; Willems L; Park S; Raynaud S; Cluzeau T; Clappier E; Fenaux P; Adès L; Margueron R; Wassef M; Alsafadi S; Chapuis N; Kosmider O; Solary E; Constantinou A; Stern MH; Droin N; Palancade B; Miotto B; Chédin F; Fontenay M
Nat Commun; 2024 Apr; 15(1):3016. PubMed ID: 38589367
[TBL] [Abstract][Full Text] [Related]
14. Genetic landscape of recurrent ASXL1, U2AF1, SF3B1, SRSF2, and EZH2 mutations in 304 Chinese patients with myelodysplastic syndromes.
Wu L; Song L; Xu L; Chang C; Xu F; Wu D; He Q; Su J; Zhou L; Xiao C; Zhang Z; Zhao Y; Chen S; Li X
Tumour Biol; 2016 Apr; 37(4):4633-40. PubMed ID: 26508027
[TBL] [Abstract][Full Text] [Related]
15. Effect of RNA splicing machinery gene mutations on prognosis of patients with MDS: A meta-analysis.
Wang X; Song X; Yan X
Medicine (Baltimore); 2019 May; 98(21):e15743. PubMed ID: 31124956
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
